GSK (GSK) said Tuesday that an ongoing phase 3 trial evaluating linerixibat in adults with cholestatic pruritus, or relentless itching, associated with primary biliary cholangitis met its primary endpoint of significantly improving itch over 24 weeks compared with placebo.
The company said the improvement was demonstrated by a "statistically significant" reduction from baseline in monthly itch score. GSK said preliminary safety results are "generally consistent" with prior studies, but further data analysis continues.
Full results of the trial will be presented at a future scientific congress, GSK said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments